Navigation Links
TRC-NW6S

ProductsTRC-NW6S
Company Topcon America Corporation
Item TRC-NW6S
Features Total solution for diabetic screening, innovative peripheral internal fixation points, easy alignment, easy focusing, new ergonomic design, small pupil capability, auto flash intensity setting, illuminated operation pane, fluorescent capability.
Description The quick access to diabetic screening, panoramic images of the retina including peripheral area are available by using easy, semi automatic guidance of peripheral fixation.
Info Topcon America Corporation
Customer Service: (800) 223-1130
Web site: http://www.topcon.com/home.html

Related medicine products :

1. TRC-NW6SF
TAG: TRC
(Date:12/3/2008)...-- The American College of Surgeons (ACS) today re...ommittee report on resident duty hours that was re...n Optimizing Graduate Medical Trainee (Resident) H... , , ACS agrees with the IOM in its concl...our work week (averaged over four weeks) are not a...
(Date:12/3/2008)...pecific Gamma Imaging (BSGI) has,equivalent sensi...atients with,inconclusive findings after mammogra...cer, according to findings presented today at the ...th America (RSNA). BSGI is a molecular breast,ima...graphy that can identify,lesions independent of t...
(Date:12/3/2008)...c guidelines, , , WEDNESDAY, Dec. 3 (...pressure drugs was more effective than a diuretic-...diovascular problems and death in people with high...d more than 11,000 patients in the United States, ...ents took either a tablet containing benazepril (a...
(Date:12/3/2008)...wswire/ -- The following is a statement by Betsy R...ation: , , "State officials today announced...from the state,s $44 million Healthcare Stabilizat..., but the more sobering headline is the fact that ...way. While a worthy effort, clearly the needs of N...
Breaking Medicine News(10 mins):Health News:American College of Surgeons Comments on Institute of Medicine Report on Resident Duty Hours 2Health News:Molecular Breast Imaging Outperforms MRI for Patients With Inconclusive Results in the Diagnosis of Cancer 2Health News:Blood Pressure Pill Combo More Effective Than Diuretics 2
...ch in alpha-linoleic acid reduced cardiac events i...D) is a major public health problem in South Asian...high prevalence of CAD is not fully explained by c...etes and high blood pressure. Researchers in Indi...
... to a new study it is observed that thalidomide i...sed multiple myeloma patients when combined with a... Mayo Clinic in Rochester, Minn.// gave 60 newly d...ong with the synthetic steroid dexamethasone. Resu...
... engage in substantial leisure time activity, incl...acture. A new report from the long-running Nurses'... women in the US,// shows that keeping active keep... hours activity(known as metabolic equivalent task...
...racelets appear to be no better than a placebo whe...ding to a new study by doctors at the Mayo Clinic,...are hopeful that the problem could be relieved// b... the participants into two groups - one of which w...
Other Medicine News:
(Date:12/2/2008)...izon Therapeutics, Inc., a,privately held biophar...al,Phase 3 trials evaluating its lead investigati...endpoints. HZT-501, a novel, proprietary fixed-dos...motidine, demonstrated a,statistically significan...i-inflammatory drug (NSAID)-induced upper gastroin...
(Date:12/1/2008)...-- New research has found that the availability of...canner in an emergency room can significantly incr...tentially life-saving treatment. Results of the st...)-Salem Hospital in Salem, Mass., will be presente...Society of North America (RSNA). , , "The h...
(Date:12/1/2008)...Call/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VND...e world,s leading medical journals, results of cli...erimental compound tasimelteon (VEC-162). The pub...onin agonist tasimelteon (VEC-162) for transient i...trolled multicentre trials." Results are reported ...
(Date:12/1/2008)...Pte Ltd today announced the initiation of a Phase ...active JAK2 inhibitor, in leading medical centers ...myelofibrosis (CIMF). , , The trial is des...B1518 in patients with CIMF and is expected to enr...dy will assess the safety profile and evaluate the...
Breaking Medicine Technology:Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Portable CT Increases Chance of Stroke Survival and Recovery 2Portable CT Increases Chance of Stroke Survival and Recovery 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3George to receive Pulp Biology and Regeneration Award 22800 1Atchison receives Behavioral Epidemiological and Health Services Research Award 22796 1Atchison receives Behavioral Epidemiological and Health Services Research Award 22796 2Best Practice Database Adds Research on New Product Commercialization 22793 1Best Practice Database Adds Research on New Product Commercialization 22793 2ADHD Gene Doesnt Predict Response to Drugs 22791 1ADHD Gene Doesnt Predict Response to Drugs 22791 2ADHD Gene Doesnt Predict Response to Drugs 22791 3
...essed people with bipolar,disorder who are taking ...tion is no more effective than a placebo (sugar pi...h 28, 2007 in the New,England Journal of Medicine....te Systematic Treatment Enhancement Program,for Bi... trial,funded by the National Institutes of Health...
...n Valortim-Treated,Animals , PRINCETON, N.J. and A...daq: MEDX), a leading monoclonal antibody company,...logy company dedicated,to the development of biode...im, a fully human monoclonal antibody product cand...ment of anthrax,infection, has been shown to have ...
Other Medicine Technology:Study Sheds Light on Medication Treatment Options for Bipolar,Disorder 2Study Sheds Light on Medication Treatment Options for Bipolar,Disorder 3Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 2Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 3Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 4Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 5Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 6Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 7